The article you just read was brought to you by a few thousand dedicated readers. Will you join them?

Thanks for coming by The Tyee and reading one of many original articles we’ll post today. Our team works hard to publish in-depth stories on topics that matter on a daily basis. Our motto is: No junk. Just good journalism.

Just as we care about the quality of our reporting, we care about making our stories accessible to all who want to read them and provide a pleasant reading experience. No intrusive ads to distract you. No paywall locking you out of an article you want to read. No clickbait to trick you into reading a sensational article.

There’s a reason why our site is unique and why we don’t have to rely on those tactics — our Tyee Builders program. Tyee Builders are readers who chip in a bit of money each month (or one-time) to our editorial budget. This amazing program allows us to pay our writers fairly, keep our focus on quality over quantity of articles, and provide a pleasant reading experience for those who visit our site.

In the past year, we’ve been able to double our staff team and boost our reporting. We invest all of the revenue we receive into producing more and better journalism. We want to keep growing, but we need your support to do it.

Fewer than 1 in 100 of our average monthly readers are signed up to Tyee Builders. If we reach 1% of our readers signing up to be Tyee Builders, we could continue to grow and do even more.

If you appreciate what The Tyee publishes and want to help us do more, please sign up to be a Tyee Builder today. You pick the amount, and you can cancel any time.

Support our growing independent newsroom and join Tyee Builders today.
Before you click away, we have something to ask you…

Do you value independent journalism that focuses on the issues that matter? Do you think Canada needs more in-depth, fact-based reporting? So do we. If you’d like to be part of the solution, we’d love it if you joined us in working on it.

The Tyee is an independent, paywall-free, reader-funded publication. While many other newsrooms are getting smaller or shutting down altogether, we’re bucking the trend and growing, while still keeping our articles free and open for everyone to read.

The reason why we’re able to grow and do more, and focus on quality reporting, is because our readers support us in doing that. Over 5,000 Tyee readers chip in to fund our newsroom on a monthly basis, and that supports our rockstar team of dedicated journalists.

Join a community of people who are helping to build a better journalism ecosystem. You pick the amount you’d like to contribute on a monthly basis, and you can cancel any time.

Help us make Canadian media better by joining Tyee Builders today.
We value: Our readers.
Our independence. Our region.
The power of real journalism.
We're reader supported.
Get our newsletter free.
Help pay for our reporting.
Science + Tech

Legal Pot Will Mean a Boom in Canadian Cannabis Research

Let a hundred buds bloom.

By Alastair Spriggs 20 Aug 2018 |

Alastair Spriggs is an intern at The Tyee from the UBC Graduate School of Journalism. He is an Ottawa native who reports on cannabis, the environment and Indigenous-related issues.

For decades in Canada, cannabis has been a controlled substance in the eyes of the government and as tough for legitimate scientists to obtain as other illegal drugs.

Scientists and researchers must obtain an exemption from Health Canada’s Controlled Drugs and Substances Act to use cannabis for research purposes that include analytical and genetic testing in controlled environments and administration to animals or humans in a clinical trial.

“It’s on par with heroine and crack cocaine,” said Dr. M-J Milloy, a research scientist with the Vancouver-based BC Centre on Substance Use. “Only a few scientists have able to carry out this research due to the restrictive regulations.”

That’s going to change Oct. 17 when cannabis becomes legal.

Though cannabis has been under prohibition in Canada since April 23, 1923, its entry into the legal market is predicted to generate close to $6.5 billion annually in retail sales by 2020, according to a report by CIBC analysts. This number would exceed the $5.1 billion spirits market, and will come close to the $7 billion spent on wine.

Milloy argues that both recreational and medical forms of cannabis have not been taken seriously up until now. He says the drug’s entry into the legal market will make clinical research easier to conduct, and cannabis itself will be much more accessible.

“The landscape for cannabis is changing in Canada,” Milloy said. “There are more bodies who are willing and able to fund the research necessary to understand cannabis better.”

According to Dr. Jonathan Page, CEO and co-founder of Vancouver-based Anandia Labs, legalization will boost the immediacy and importance of cannabis research, primarily in its biological, sensory, clinical and societal impact.

“Scientists know a lot about cannabis, but there are still many areas that haven’t been researched effectively,” Page said.

How cannabinoids are produced

Page says a lot of basic and fundamental science remains unknown about the cannabis plant.

“Cannabis is like the Ferrari of the plant world,” Page said. “There’s no other plant that can produce cannabinoids in such high quantities.”

The most active cannabinoids produced by the cannabis plant are THC and CBD. THC is known to cause the psychoactive effects felt from cannabis, and CBD, which is shown to have anti-inflammatory and anti-anxiety properties.

These active chemical ingredients are produced in abundance in the plant’s trichomes — the fine outgrowths or appendages on the plant that produce the hundreds of known cannabinoids, terpenes and flavonoids that make cannabis strains potent, unique and effective.

Trichomes are not unique to cannabis, and their production can be observed in many species of plants throughout nature.

They often function as a defence mechanism by releasing gooey and smelly residues that deter insects from eating the plant and its seeds. Female flowers are especially covered in trichomes to protect their fat and oil-rich seeds.

“We understand the power of trichomes and the biochemical pathways leading to THC and CBD, but we don’t know why cannabis trichomes produce such high levels of specialized chemicals,” Page said.

According to Page, a common theory is that cannabis produces THC as a defence function to deter predators by making them high. But insects don’t have cannabinoid receptors, and the cannabis plant makes THCA, which has no psychoactive properties. THCA must be heated to create THC, the active form that gives a user a high.

Researchers are going to emphasize the genetics and mechanisms of how cannabinoids are produced in certain strains as Canada transitions to a legalized market, he added.

“This research will help us to better our chemical understanding of certain strains and breed cannabis strains that can more effectively meet recreational and medical consumer needs.”

Dr. Jonathan Page is the co-founder of Anandia Labs, a cannabis genetics and research firm based at UBC. The firm was recently purchased by Aurora Cannabis Inc. for a value of approximately $115 million. Photo by Goya Ngan.

Page says the difference between indica and sativa strains also requires more research.

“I’m interested in ways of classifying cannabis that help people understand how they can use it most effectively,” Page added. “Our current understanding is based on consumer and patient anecdotes.”

“I think we’re going to see an attempt to figure out the sensory appeal as to why people smoke some strains and some smoke others. Some strains keep you awake all night, others make you fall asleep. Scientists have no idea how this works.”

He believes the future of this research will be driven by the recreational market.

Cannabis dispensaries and retailers classify cannabis product as an indica, a sativa or a hybrid strain. Similar to a menu board at a restaurant, all available products are sorted by the two classifications. An indica strain is reportedly a “sedative type high, described as a body stone." In contrast, a sativa strain is “an uplifting high, that causes an energizing effect.”

According to Page, consumers have become accustomed to these groupings, but there is limited chemical and genetic analysis to accurately support the classification.

“A broader genetic and chemical investigation into the psychoactivity and sensory properties of cannabis will be happening after legalization,” he added.

Understanding the power of cannabinoids

Philippe Lucas, vice-president of patient access and research at Tilray, a Nanaimo-based medical cannabis production and research firm, says the legalization of marijuana in Canada won’t impact the nature of research in medical applications on a clinical level.

Lucas believes the industry has made significant leaps in understanding the relative safety of cannabis and cannabinoids, particularly in comparison to other commonly prescribed pharmaceuticals. The next step will be better understanding the efficacy of different cannabinoids alone and in combination with a greater range of conditions and symptoms.

In a recent clinical trial, findings showed cannabis oil as an effective treatment for pediatric epilepsy patients suffering from Dravet Syndrome. Researchers found a reduction in seizures and an overall improvement of quality of life in their patients.

Lucas says that most clinical research is at an intermediate stage and that more work is necessary to actually gain market approval for cannabis-based medicines.

Lucas adds: “Further research needs to be done on specific dosages and methods of administration in the treatment of pain, mental health and other chronic conditions, and legalization may make clinical and observational research easier to conduct.”

Social impact

Canada is embarking on a global experiment as the first G7 nation to make marijuana legal.

Yet there are still many uncertainties related to health, social and economic implications of cannabis legalization and regulation, according to Dr. Samuel Weiss, the scientific director of neurosciences, mental health and addiction at the Canadian Institutes of Health Research.

Most recently, the federal government has invested $1.4 million in 14 short-term research projects across Canada as a rapid-response approach to build cannabis research capacity — two B.C.-based researchers received funding. Dr. Bonnie Leadbeater, professor of psychology at the University of Victoria, recently published a study that showed that students who try marijuana at an early age and use it often are more likely to have poor health outcomes and less occupational and educational success. Additionally, Dr. Zach Walsh, professor of psychology at the University of British Columbia, is researching the impact of cannabis legalization on campus health.

Some of the other research themes supported by investment include: mental health and addictions; violence, injuries and road safety; pregnancy and childhood health; therapeutic benefit; and intervention research in substance misuse.

The CIHR is expected to make another $3 million available to fund more research in the coming months.  [Tyee]

Read more: Health, Science + Tech

Share this article

The Tyee is supported by readers like you

Join us and grow independent media in Canada

Facts matter. Get The Tyee's in-depth journalism delivered to your inbox for free

Tyee Commenting Guidelines

Do not:

  •  Use sexist, classist, racist or homophobic language
  • Libel or defame
  • Bully, threaten, name-call or troll
  • Troll patrol. Instead, downvote, or flag suspect activity
  • Attempt to guess other commenters’ real-life identities


  • Verify facts, debunk rumours
  • Add context and background
  • Spot typos and logical fallacies
  • Highlight reporting blind spots
  • Ignore trolls and flag violations
  • Treat all with respect and curiosity
  • Stay on topic
  • Connect with each other


The Barometer

Tyee Poll: What Coverage Would You Like to See More of This Year?

Take this week's poll